Craig Ellins has been appointed as the Chief Science Officer at Hypha Labs Inc., formerly known as Digipath Inc. following the sale of its cannabis lab assets. With a focus on developing innovative technology for creating active ingredients in functional mushrooms like psilocybin, the company utilizes its patent-pending bioreactor design.
Ellins is recognized as a forward-thinker in emerging technologies and industries, with a track record of success with companies including One World Pharma and GB Sciences. His expertise lies in recognizing and seizing early-stage opportunities in new markets, particularly in the cannabis industry. Hypha Labs is confident that Ellins’ experience in the cannabis sector will be beneficial in navigating the psilocybin market, which they believe will resemble the cannabis industry.
